SCHEMBL7204248

SCHEMBL7204248

NC(=O)N1CCC(S(=O)(=O)c2ccc(Oc3cccnc3)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 6/20 0.42
MMP2 P08253 3/20 0.42
ADAM17 P78536 1/20 0.42
MMP13 P45452 5/20 0.39
MMP3 P08254 2/20 0.38
MMP9 P14780 2/20 0.38
MMP14 P50281 2/20 0.38
MMP12 P39900 1/20 0.38
TRPV4 Q9HBA0 1/20 0.37
ALDH1A1 P00352 2/20 0.36
SYK P43405 1/20 0.36
HTT P42858 1/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
BTK Q06187 1/20 0.36
ABL1 P00519 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7207163 0.90 MMP1 (0.45) MMP1MMP2MMP13MMP3MMP9
SCHEMBL7203051 0.89 MMP1 (0.39) MMP1MMP2ADAM17MMP13MMP3
SCHEMBL7200542 0.86 ADAMTS4 (0.42) MMP1MMP13MMP3MMP9MMP14
SCHEMBL7292210 0.86 GHSR (0.46) TRPV4ABL1CA12CA1CA2
SCHEMBL7204544 0.84 MMP1 (0.41) MMP1MMP2ADAM17MMP13MMP3
SCHEMBL7199692 0.84 PARP10 (0.41) MMP1MMP2ADAM17MMP13MMP3
SCHEMBL7203058 0.84 MMP9 (0.47) MMP1MMP2MMP13MMP3MMP9
SCHEMBL7204562 0.84 MMP13 (0.51) MMP1MMP2MMP13MMP3MMP9
SCHEMBL7205634 0.83 MMP13 (0.55) MMP1MMP2MMP13MMP3MMP9
SCHEMBL7199646 0.83 MMP1 (0.43) MMP1MMP2MMP13MMP3MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP1 8/4885MMP2 13/4885ADAM17 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.